Expression of cell cycle regulator p57kip2, cyclinE protein and proliferating cell nuclear antigen in human pancreatic cancer: An immunohistochemical study

Abstract

AIM: To investigate the effects of p57^kip2, cyclinE protein and proliferating cell nuclear antigen (PCNA) on occurrence and progression of human pancreatic cancer.

METHODS: The expression of p57^kip2, cyclinE protein and PCNA in tumor tissues and adjacent tissues from 32 patients with pancreatic cancer was detected by SP immunohistochemical technique.

RESULTS: The positive expression rate of p57^kip2 protein in tumor tissues was 46.9%, which was lower than that in adjacent pancreatic tissues (χ² = 5.317, P<0.05). p57^kip2 protein positive expression remarkably correlated with tumor cell differentiation (P<0.05), but not with lymph node metastasis (P>0.05). The positive expression rate of cyclinE protein in tumor tissues was 68.8%, which was higher than that in adjacent pancreatic tissues (χ² = 4.063, P<0.05). CyclinE protein positive expression significantly correlated with tumor cell differentiation and lymph node metastasis (P<0.05). The positive expression rate of PCNA in the tumor tissues was 71.9%, which was higher than that in adjacent pancreatic tissues (χ² = 5.189, P<0.05). PCNA positive expression remarkably correlated with tumor cell differentiation and lymph node metastasis (P<0.05).

CONCLUSION: The decreased expression of p57^kip2 and/or overexpression of cyclinE protein and PCNA may contribute to the occurrence and progression of pancreatic cancer. p57^kip2, cyclinE protein, and PCNA play an important role in occurrence and progression of pancreatic cancer.

Key Words: p57^kip2; CyclinE; PCNA; Human pancreatic cancer

INTRODUCTION

Abnormality in mammalian cell cycle regulation is an important cause of cell proliferation and oncogenesis[1]. Orderly progression of the cell cycle is controlled by a family of cyclins and cyclin-dependent kinases (CDKs), which are restrictively counterbalanced by CDK inhibitors (CDKIs)[2]. Two distinct families of CDKIs, INK4, and CIP/KIP families, which regulate the activity of cyclin-CDK complexes, have been described[3]. The CIP/KIP family, including p21, p27, and p57 proteins, harbors homologous CDK-binding domains or functions of cyclin-CDK complexes and causes the cell cycle to arrest in G1 phase. CyclinE protein is a positive regulator of cell cycle, which promotes the transfer from G1 to S phase. The expression of PCNA remarkably correlates with status of cell proliferation. There are few reports about the relationship between p57^kip2 protein as negative factor of cell cycle regulation and pancreatic cancer. In this study, the expression of p57^kip2, cyclinE protein, and PCNA in pancreatic cancer tissues and adjacent tissues was detected by immunohistochemical technique to investigate the effects of p57^kip2, cyclinE protein, and PCNA on occurrence and progression of human pancreatic cancer.

MATERIALS AND METHODS

Patients and tumor samples

Thirty-two specimens of primary human pancreatic cancer were collected from pancreatic resection performed in the Department of General Surgery, General Hospital of Shenyang Military Command. There were 20 male and 12 female patients, with a mean age of 59.5 years (26-72 years). Nineteen patients had well-differentiated pancreatic cancer, 13 had moderately or poorly-differentiated pancreatic cancer, and 12 had lymph node metastasis. All patients were confirmed by clinicopathological diagnosis. These specimens were fixed in 10% buffered formalin and embedded in paraffin. All sections stained with hematoxylin and eosin were reviewed and kept for further studies.

Immunohistochemical study

Four-micrometer-thick sections from the tissues were cut for immunohistochemical study. The expression of p57^kip2, cyclinE protein, and PCNA was assessed by SP immunohistochemical method using anti-human p57^kip2 mAb (57P06), anti-human cyclinE protein mAb (13A3), anti-human PCNA mAb (PC10), and the UltraSensitive^TM SP kit (kit-9720). Immunohisto-chemical staining for these proteins was then performed according to the UltraSensitive^TM SP kit manual. All reagents were supplied by Maixin-Bio Co., Fuzhou, China. The cells with brown-yellow granules in the nuclei or cytoplasm were taken as positive. Five hundred cells on each slide were counted. The slides were classified as negative (-), positive (+), strong positive (++), and strongest positive (+++) according to the count of positive cells for p57^kip2 and cyclinE proteins less than 10%, 10-25%, 25-50%, and more than 50%, respectively. The slides was distinguished as negative (-), and positive (+) when the count of positive cells were less than 50% and over 50% for PCNA resp-ectively.

Statistical analysis

The χ² test and Fisher’s exact test were used in the analysis by SAS system statistical software (release 6.12). P<0.05 was considered statistically significant.

RESULTS

Expression of p57^kip2 protein

The p57^kip2 protein was located in the nuclei or cytoplasm of normal pancreatic cells and positive pancreatic cancer cells with brown-yellow granules (Figure 1A).The positive expression rate of p57^kip2 protein in tumor tissues was 46.9%, which was lower than that in adjacent pancreatic tissues (χ² = 5.317, P<0.05). The positive expression rate of p57^kip2 protein in the moderately or poorly differentiated tumor tissues was 23.1%, which was lower than that in well-differentiated tumor tissues (χ² = 4.979, P<0.05). The positive expression rate of p57^kip2 protein in lymph node metastasis group was 25.0%, which was lower than that in non-lymph node metastasis group (P>0.05, Table 1).

Table 1 Expression of p57^kip2 protein in pancreatic cancer tissues.

	p57kip2 protein expression
Characteristics	-	+	++	+++	Rate (%)
Tumor tissue	17	11	3	1	46.9a
Well-differentiated	7	9	2	1	63.2c
Moderately or
poorly-differentiated	10	2	1	0	23.1c
Lymph node metastasis	9	2	1	0	25.0e
Non-lymph node
metastasis	8	9	2	1	60.0e
Adjacent tissue	8	13	6	5	75.0a

^aP<0.05,

^cP<0.05,

^eP>0.05 vs others.

Figure 1 P57^kip2 protein in well-differentiated pancreatic adenocarcinoma (A), cyclin E protein in poorly-differentiated pancreatic adenocarcinoma (B), and PCNA protein in moderately-differentiated pancreatic adenocarcinoma (C).

Expression of cyclinE protein

CyclinE protein was located in the nuclei or cytoplasm of normal pancreatic cells and positive pancreatic cancer cells with brown-yellow granules (Figure 1B). The positive expression rate of cyclinE protein in tumor tissues was 68.8%, which was higher than that in adjacent pancreatic tissues (χ² = 4.063, P<0.05). The positive expression rate of cyclinE protein in moderately or poorly differentiated tumor tissues was 84.6%, which was higher than that in well-differentiated tumor tissues (χ² = 5.128, P<0.05). The cyclinE protein positive expression rate in lymph node metastasis group was 91.7%, which was higher than that in non-lymph node metastasis group (χ² = 4.693, P<0.05, Table 2).

Table 2 Expression of cyclinE protein in pancreatic cancer tissues.

Characteristics	CyclinE protein expression
	-	+	++	+++	Rate (%)
Tumor tissue	10	7	9	6	68.8a
Well-differentiated	9	5	4	1	52.6c
Moderately or
poorly-differentiated	1	1	6	5	84.6c
Lymph node metastasis	1	1	5	5	91.7e
Non-lymph node
metastasis	9	6	4	1	55.0e
Adjacent tissue	18	6	8	0	43.8a

^aP<0.05,

^cP<0.05,

^eP<0.05 vs others.

Expression of PCNA

PCNA was located in the nuclei of normal pancreatic cells and positive pancreatic cancer cells with brown-yellow granules (Figure 1C). The positive expression rate of PCNA in tumor tissues was 71.9%, which was higher than that in adjacent pancreatic tissues (χ² = 5.189, P<0.05). The positive expression rate of PCNA in moderately or poorly diffe-rentiated tumor tissues was 92.3%, which was higher than that in well-differentiated tumor tissues (χ² = 4.522, P<0.05). The positive expression rate of PCNA in lymph node metastasis group was 100%, which was higher than that in non-lymph node metastasis group (χ² = 7.513, P<0.05, Table 3).

Table 3 Expression of PCNA in pancreatic cancer tissues.

Characteristics	PCNA protein expression
	-	+	Rate (%)
Tumor tissue	9	23	71.9a
Well-differentiated	8	11	57.9c
Moderately or poorly-differentiated	1	12	92.3c
Lymph node metastasis	0	12	100e
Non-lymph node metastasis	9	11	55.0e
Adjacent tissue	18	14	43.8a

^aP<0.05,

^cP<0.05,

^eP<0.05 vs others.

Relationship between expression of p57^kip2 and cyclinE proteins

The cyclinE protein positive expression rate in tumor tissues of the p57^kip2 protein positive expression group and the p57^kip2 protein negative expression was 60.0% and 76.5% respectively. There was no significant correlation between the two groups (r = -0.11211, P>0.05, Table 4).

Table 4 Relationship between expression of p57^kip2 and cyclinE proteins.

p57kip2	CyclinE protein expression
	-	+	++	+++	Rate (%)
–	4	4	6	3	76.5
+	4	3	2	2
++	2	0	0	1	60.0
+++	0	0	1	0

DISCUSSION

Studies in recent years have shown that G₁ phase regulation is a complex procedure[4-7]. p57^kip2 gene is located in chromosome 11p15.5, and p57^kip2 protein is a cell cycle inhibitor with molecular weight of 57 ku, which is included in the CIP/KIP family and similar to p21 and p27 proteins in functions[8,9]. Lee et al[10] suggested that the tumor suppressor mechanism of p57^kip2 protein may be integrated with cyclin-CDK complexes and makes cell cycle to arrest in the G₁ phase. Kondo et al[11] considered that paternal alleles of p57^kip2 are imprinted, maternal alleles of p57^kip2 are expressed in the normal status, loss of imprinting and imprinting mistakes of p57^kip2 lead to a decrease at level of gene expression in tumors. Matsumoto et al[12] reported that p57^kip2 protein positive expression rate is 43.3±3.2% in patients with esophageal squamous cell carcinoma. From then on, studies about p57^kip2 protein expression in human colorectal carcinoma[13], hepatocellular carcinoma[14,15], prostate tumor[16], neoplastic thyroid tissues[17], epithelial ovarian tumor[18], extrahepatic bile duct carcinoma and intrahepatic cholangiocellular carcinoma have been reported[19,20], but few reports on the relationship between p57^kip2 protein expression and pancreatic cancer are available[21]. In this study, we found that the positive expression rate of p57^kip2 protein in pancreatic cancer tissues was significantly lower than that in adjacent pancreatic tissues. The worse the cancer cell differentiation, the lower was the p57^kip2 protein expression, and there was no correlation between the reduced expression of p57^kip2 protein and lymph node metastasis. The results suggest that reduced expression of p57^kip2 protein correlates with the occurrence and malignant degree of pancreatic cancer. CyclinE protein is a positive regulating factor in the cell cycle and promotes the genesis and progression of tumors[22-24]. Our results suggest that overexpression of cyclinE is associated with the genesis and malignant degree, as well as lymph node metastasis of pancreatic cancer. PCNA is a δ-assistant factor of DNA synthetase, takes part in DNA biological synthesis and regulates cell cycle and cell proliferation by tetramer with cyclin, CDK and p21. Overexpression of PCNA is associated with a variety of tumors of digestive system including human colorectal cancer[25], gastric cancer[26], hepatocellular carcinoma[27], pancreas tumor[28,29]. The results in the present study suggest that overexpression of PCNA is associated with the occurrence and progression of pancreatic cancer, and malignant proliferation status of pancreatic cancer determined by expression of PCNA is of practical value. Our results suggest that cell proliferative activity is high for the negative or reduced expression of p57^kip2 protein. Furthermore, p57^kip2 protein plays a role in suppressing cell proliferation. Our findings are in accordance with the results of previous studies[5].

In summary, decreased expression of p57^kip2 and/or overexpression of cyclinE protein and PCNA might contribute to the occurrence and progression of pancreatic cancer. The p57^kip2, cyclinE protein, and PCNA might play an important role in occurrence and progression of pancreatic cancer.